CR20210602A - Compuestos de pirrolidina - Google Patents

Compuestos de pirrolidina

Info

Publication number
CR20210602A
CR20210602A CR20210602A CR20210602A CR20210602A CR 20210602 A CR20210602 A CR 20210602A CR 20210602 A CR20210602 A CR 20210602A CR 20210602 A CR20210602 A CR 20210602A CR 20210602 A CR20210602 A CR 20210602A
Authority
CR
Costa Rica
Prior art keywords
sub
och
compounds
formula
pyrrolidine compounds
Prior art date
Application number
CR20210602A
Other languages
English (en)
Inventor
Buezo Nuria Diaz
Gil Gema Consuelo Sanz
Perez Jose Antonio Martinez
Blanco Celia Lafuente
Soler Julian Priego
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20210602A publication Critical patent/CR20210602A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la Fórmula (I) en donde L se selecciona del grupo que consiste en -CH<sub>2</sub>NHCH<sub>2</sub>-, -CH<sub>2</sub>NH-, -NH-, -S-, -S(O)-, -S(O)<sub>2</sub>-, -O-, -OCH<sub>2</sub>-, -OCH<sub>2</sub>CH<sub>2</sub>O-, -NHSO<sub>2</sub>NH-, (II) y (III), o una sal farmacéuticamente aceptable de estos; un compuesto de la fórmula: (IV), procesos para preparar los compuestos y sus sales, una composición farmacéutica y métodos para tratar pacientes que necesiten dicho tratamiento.
CR20210602A 2019-06-07 2020-06-03 Compuestos de pirrolidina CR20210602A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382477 2019-06-07
PCT/US2020/035825 WO2020247429A1 (en) 2019-06-07 2020-06-03 Pyrrolidine compounds

Publications (1)

Publication Number Publication Date
CR20210602A true CR20210602A (es) 2022-01-06

Family

ID=66821161

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210602A CR20210602A (es) 2019-06-07 2020-06-03 Compuestos de pirrolidina

Country Status (22)

Country Link
US (2) US11286249B2 (es)
EP (1) EP3980409A1 (es)
JP (2) JP6940717B2 (es)
KR (3) KR102477481B1 (es)
CN (1) CN114008021A (es)
AU (1) AU2020287599B2 (es)
BR (1) BR112021023347A2 (es)
CA (1) CA3140869A1 (es)
CL (1) CL2021003202A1 (es)
CO (1) CO2021016295A2 (es)
CR (1) CR20210602A (es)
DO (1) DOP2021000254A (es)
EA (1) EA202193007A1 (es)
EC (1) ECSP21088515A (es)
IL (1) IL288174A (es)
JO (1) JOP20210319A1 (es)
MA (1) MA56115A (es)
MX (1) MX2021014913A (es)
PE (1) PE20220134A1 (es)
SG (1) SG11202113244UA (es)
WO (1) WO2020247429A1 (es)
ZA (1) ZA202109251B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3235992A1 (en) 2021-11-03 2023-05-11 Liang Tan Substituted phenylpropionic acid derivative and use thereof
WO2023146785A1 (en) 2022-01-26 2023-08-03 Eli Lilly And Company Pyrrolidine compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003016265A1 (ja) * 2001-08-17 2004-12-02 エーザイ株式会社 環状化合物およびｐｐａｒアゴニスト
AU2003300438A1 (en) * 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
CA2549995C (en) * 2003-12-24 2011-11-15 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses

Also Published As

Publication number Publication date
BR112021023347A2 (pt) 2022-04-12
AU2020287599B2 (en) 2023-10-19
EA202193007A1 (ru) 2022-03-25
CO2021016295A2 (es) 2021-12-10
KR102629923B1 (ko) 2024-01-30
WO2020247429A1 (en) 2020-12-10
CL2021003202A1 (es) 2022-09-09
IL288174A (en) 2022-01-01
MA56115A (fr) 2022-04-13
US20210253559A1 (en) 2021-08-19
JP6940717B2 (ja) 2021-09-29
EP3980409A1 (en) 2022-04-13
JP2021191784A (ja) 2021-12-16
MX2021014913A (es) 2022-01-18
DOP2021000254A (es) 2022-01-16
AU2020287599A1 (en) 2022-01-06
US11286249B2 (en) 2022-03-29
JOP20210319A1 (ar) 2023-01-30
KR20220018494A (ko) 2022-02-15
PE20220134A1 (es) 2022-01-27
US20220169636A1 (en) 2022-06-02
CN114008021A (zh) 2022-02-01
SG11202113244UA (en) 2021-12-30
ECSP21088515A (es) 2022-01-31
JP2021524498A (ja) 2021-09-13
CA3140869A1 (en) 2020-12-10
KR20230004890A (ko) 2023-01-06
KR20240014618A (ko) 2024-02-01
KR102477481B1 (ko) 2022-12-15
ZA202109251B (en) 2024-04-24

Similar Documents

Publication Publication Date Title
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
MX2020007633A (es) Péptidos macrocíclicos contra acinetobacter baumannii.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
CR20210627A (es) Derivados de benzisoxazol sulfonimada
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
CR20230310A (es) Inhibidores de prmt5
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
CR20210602A (es) Compuestos de pirrolidina
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
BRPI0409230A (pt) formas de dosagem compreendendo ag013736
MX2023002547A (es) Compuestos novedosos como inhibidor de histona desacetilasa 6 y composicion farmaceutica que comprende los mismos.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
MX2022006333A (es) Compuesto triheterociclico como inhibidor de jak y uso del mismo.
UA99492C2 (ru) Производные 1,3-дигидро-5-изобензофуранкарбонитрила и его фармацевтическая композиция для лечения преждевременной эякуляции
MX2021012105A (es) Compuestos de pirrol.
MX2023006751A (es) Nuevo derivado de camptotecina, composicion que comprende el mismo y su uso.
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
SE0201837D0 (sv) Chemical compounds
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer